No Rx for big drugmakers accused of fixing prices


The pharmaceutical industry is in hot water. For years the Federal Trade Commission has scrutinized drug pricing, taking a hard look at so-called reverse payments that branded drugmakers use to settle patent litigation and prevent early entry by competitors with cheaper generic drugs. But those deals must be examined within